Quality Indicators - Anatomic Pathology- HSC/STC Jul-Sep 2 nd Qtr. Apr-Jun 1 st Qtr

Similar documents
Quality assurance and quality control in pathology in breast disease centers

Quality Assurance and Quality Control in the Pathology Dept.

Lessons learned in the use of digital imaging at Memorial Sloan Kettering Cancer Center

Interpretive Diagnostic Error Reduction in Surgical Pathology and Cytology

NordiQC External Quality Assurance in Immunohistochemistry

Breast Cancer Diversity Various Disease Subtypes Clinical Diversity

An Audit of Pleural Fluid Sampling and Diagnostics at James Cook Hospital, Middlesbrough

Version 2 of these Guidelines were drafted in response to published updated ASCO/CAP HER2 test Guideline Recommendations-

PROTOCOL SENTINEL NODE BIOPSY (NON OPERATIVE) BREAST CANCER - PATHOLOGY ASSESSMENT

Breast Test Wales Screening Division Public Health Wales

Aspects of quality in breast pathology. Andrew Lee Nottingham University Hospitals

Measure Specifications Measure Description

Quality Control/Quality Assurance in Diagnostic Immunohistochemistry

COMPUTER-AIDED HER-2/neu EVALUATION IN EXTERNAL QUALITY ASSURANCE (EQA) OF BREAST CANCER SCREENING PROGRAMME

Optimal algorithm for HER2 testing

FAQs for UK Pathology Departments

FAQs about Provider Profiles on Breast Cancer Screenings (Mammography) Q: Who receives a profile on breast cancer screenings (mammograms)?

Addendum report coding for the National Quality Improvement Programme in Histopathology: a multi-institutional audit

Brighton and Sussex University Hospitals NHS Trust Board of Directors. Mark Smith Chief Operating Officer

Guideline. Associated Documents ASCO CAP 2018 GUIDELINES and SUPPLEMENTS -

Barriers to Understanding

Applying Risk Management Principles to QA in Surgical Pathology: From Principles to Practice

HIV Viral Load Quality Assessment Program Summary for Panel HIVVL 2018Oct26

MICHIGAN PATHOLOGY QUALITY SYSTEM (MPQS)

GOALS AND OBJECTIVES BREAST PATHOLOGY

HISTOPATHOLOGY DEPARTMENT

One Palliative Care Annual Report

Cases requiring intra-departmental or extra-departmental consultation

1. Q: What has changed from the draft recommendations posted for public comment in November/December 2011?

Layered-IHC (L-IHC): A novel and robust approach to multiplexed immunohistochemistry So many markers and so little tissue

18 Week 92% Open Pathway Recovery Plan and Backlog Clearance

October Billing and compliance. Coagulation. Immunohistochemistry. Immunology. Referral testing ICD 10

The Cancer Research UK Stratified Medicine Programme: Phases One and Two Dr Emily Shaw

Stage Data Capture in Ontario

Making the Most of Your Cancer Registry

National Cancer Peer Review Sarcoma. Julia Hill Acting Deputy National Co-ordinator

Quantitative Image Analysis of HER2 Immunohistochemistry for Breast Cancer

Quality Control and Assurance in Anatomic Pathology: The Moffitt Experience

Diagnostic Detectives: Medical Laboratory Professionals A Closer Look at Careers in Histology

Histopathology National Quality Improvement Programme Data Report 2015 Edition 3 created July 2016

Human Papillomavirus Testing in Head and Neck Carcinomas

117 Applying Risk Management Principles to QA in Surgical Pathology: From Principles to Practice. Gregory Flynn MD

CIHRT Exhibit P-1830 Page 1

Assessment Run B HER-2

IMPLEMENTING RECOVERY ORIENTED CLINICAL SERVICES IN OPIOID TREATMENT PROGRAMS PILOT UPDATE. A Clinical Quality Improvement Program

Gastrointestinal PATHOLOGY FELLOWSHIP

NPQR 2018 Qualified Clinical Data Registry (QCDR) Measures 21_18247_LS.

Reviewer's report. Version: 1 Date: 24 May Reviewer: Cathy Moelans. Reviewer's report:

Quality, Patient Safety and Error Reduction in Cytopathology

4. Monitoring of PAP test with Cervical Biopsy Correlations

Brief Formalin Fixation and Rapid Tissue Processing Do Not Affect the Sensitivity of ER Immunohistochemistry of Breast Core Biopsies

National Cancer Peer Review Programme

Kansas EMS Naloxone (Narcan) Administration

COLORECTAL SCREENING PROGRAMME: IMPACT ON THE HOSPITAL S PATHOLOGY SERVICES SINCE ITS INTRODUCTION.

Review of cellular pathology governance, breast reporting and immunohistochemistry at. Sherwood Forest Hospitals NHS Foundation Trust

Flu Watch. MMWR Week 3: January 14 to January 20, and Deaths. Virologic Surveillance. Influenza-Like Illness Surveillance

HIV Viral Load Quality Assessment Program Summary for Panel HIVVL 2017Oct27

MEDICAL POLICY. Proprietary Information of YourCare Health Plan

ANATOMICAL PATHOLOGY TARIFF

GYNECOLOGICAL PATHOLOGY FELLOWSHIP PROGRAM

QA Processes. Philip DaCosta BSCP QA Lead, Yorkshire & the Humber September 2013

Digital Pathology and CAP Guidelines

VDx: Unlocking Complex Diagnostics

Trust Board of Directors Public. Denise Gale. For Assurance and Information NOT APPLICABLE NOT APPLICABLE NOT APPLICABLE NOT APPLICABLE

Flu Watch. MMWR Week 4: January 21 to January 27, and Deaths. Virologic Surveillance. Influenza-Like Illness Surveillance

Conflict of Interest. Thank you. I have no relevant conflicts of interest in regards to the content of this presentation.

Joseph G. Mathew PGY-3 Anatomical Pathology. Michael Bonert, Asghar Naqvi McMaster University Hamilton, Ontario, CANADA

An Information System for Improving Clinical Laboratory Outcomes

An Updated Approach to Colon Cancer Screening and Prevention

CAP Companion Meeting at USCAP Quality and Patient Safety in Anatomic Pathology: Practical Solutions. Surgical Pathology

Welcome! HER2 TESTING DIAGNOSTIC ACCURACY 4/11/2016

CHESHIRE PATHOLOGY SERVICES

The impact of proficiency testing on lab immunoassays

Disclosures. Relevant Financial Relationship(s): List or Nothing to Disclose. Off Label Usage: List or Nothing to Disclose 12/9/2016

Ms Masabata Annah Motaung, Agricultural Research Council-Onderstepoort Veterinary Institute

HISTOPATHOLOGY. Introduction

How effective is current clinical trial QA

Analysis of Immunohistochemical Stain Usage in Different Pathology Practice Settings

CELLULAR PATHOLOGY TURNAROUND TIMES

th Medical Group Report Card

Topics Cognitive Objective requirements. Psychomotor Objective Requirements. Affective Objectives. Vocabulary. Cognitive Objective requirements

A nationwide telepathology consultation and quality control program in China: implementation and result analysis

Scottish Pathology Network (SPAN) Progress Report Oct 2008

NPQR Quality Payment Program (QPP) Measures 21_18247_LS.

Reporting of Breast Cancer Do s and Don ts

Department of Pathology Presentation to Dr. Garcia

HER2 status assessment in breast cancer. Marc van de Vijver Academic Medical Centre (AMC), Amsterdam

2014 Continuing Compliance Master Series Best Practices in Alternative Assessment of Performance

The Safety of Convenience-Size Plastic Beverage Bottles

Evolution of Pathology

Greater Manchester & Cheshire Guidelines for Pathology Reporting for Oesophageal and Gastric Malignancy

Breast cancer: Antibody selection, protocol optimzation controls and EQA

Study Finds Lung Cancer Subtype Test from UNC, Startup GeneCentric to be Accurate, Reproducible

When in doubt, ask an expert

Molecular Testing Updates. Karen Rasmussen, PhD, FACMG Clinical Molecular Genetics Spectrum Medical Group, Pathology Division Portland, Maine

UW Medicine Neuropathology

NSABP: FB-11. Shannon Puhalla, MD

College of American Pathologists. Pathology Performance Measures included in CMS 2012 PQRS

SURGICAL PATHOLOGY - HISTOLOGY

Clinical Microbiology CLS 2019 Clinical Microbiology Laboratory Scheme Application Form

Transcription:

Eastern Health Volume 86 Page 001 CIHRT Exhibit P-3595 Page 1 INDICATOR Financial Overtime Hours / FTE Workload Increase - FTE equivalent Workload Quality Indicators - Anatomic Pathology- HSC/STC TOTAL 2006-07 78.75 hrs 1.8 FTE Apr-Jun 1 st Qtr 17.9 hrs 0.48 FTE Jul-Sep 2 nd Qtr 26.0 hrs 0.29 FTE 2007-08 Oct-Dec 3 rd Qtr 27.2 hrs 0.60 FTE Jan-Mar 4 th Qtr 27.2 hrs 0.54 FTE TOTAL 98.3 hr 1.91 FTE # surgical cases 28,075 7,155 6,342 7,127 7,489 28,113 # procedures 426,686 106,723 97,736 107,430 113,516 425,405 # units 2,709,332 666,672 613,999 685,273 710,833 2,673,777 25/30 1 (83.3%) 59 / 63 1 (93.6%) 127/138 1 Random Frozen Section / Final Correlation 6 (92.8%) Cases referred to Dynacare for diagnosis 8487 (30%) 2653 (37%) 1194 (18%) 488 (7%) 1202 (16%) 5537 (19%) Cases referred for consultation 3 0.95% (268) 1.5% (105) 1.1% (68) 1.1% (82) 0.8% (59) 1.1% (314) 9 cases 9 cases 9 cases 3 cases 30 cases Prostate quality review correlation 4,6 N/A 1 discrepancy 0 discrepancy 0 discrepancy 0 discrepancy 3.3% discrepancy 4 Mean Turnaround time-surgical cases 5 7.5 days 5.8 days 5.5 days 6.2 days 6.8 days 6.1 days QA activities (compliance audits) Temp check- fridges-ihc Lab Temp check- stain oven - HSC Temp check-embedding centre 85% 1. Frozen Section Reviews Discrepancies not included when considered minor, ie not significant to patient care. 2. Cytology / Surgical Correlation of Head & Neck cases 162 cases reviewed; 27 cases insufficient material 3. A College of American Pathologists Q-Probes multi-institutional study found an extra-departmental consultation rate of 0.5% 4. Approximately 10% of prostate cases are sent to Calgary Lab Services for quality review. For this purpose, a discrepancy is defined as a report which disagrees significantly from the original report. There was one case with significant discrepancy; 4 cases with a minor discrepancy with little to no significance to patient care. 5. National and international recommended turnaround times, given ideal conditions and staffing. Specimens requiring more tests, prolonged fixation, decalcification, special stains, outside consultation will require longer turnaround time (Urgents: 80% completed in 24 hours, Biopsies: 80% completed in 48 hours, Routines: 80% completed in 72 hours) Mean is calculated, excluding outlier values. 6. A multi-institutional study by Raab, Nakhleh, and Ruby reports a discrepancy rate of 6.7% for pathology reports. More than 1% of these errors may be associated with patient harm

Eastern Health Volume 86 Page 002 CIHRT Exhibit P-3595 Page 2 INTERNAL QUALITY ASSURANCE & REVIEWS 1. Staining- Quality Control A quality control slide is run with every stain to ensure that the quality of the stain is appropriate prior to distribution.of the slides to the pathologists for interpretation. Documentation of staining quality is maintained in the Meditech Pathology module. 2. Random Case Reviews - An internal review of one per cent of cases is done as a quality assurance activity. The activity alternates monthly between a specific clinical case-type and random review of all case types. These identify technical and reporting issues that can be addressed. The aspects reviewed are: Clerical Errors Turnaround time Histology review Special stains Immunohistochemistry Accuracy Completeness Random reviews from October 2007 and January 2008 demonstrated good results in all aspects, except turnaround time which averaged 6.1 days for October review; the January review was for a new pathologist and the TAT was expectedly higher than average. 3. Quality / Difficult Case Rounds Challenging cases are reviewed and discussed at Pathology Rounds and diagnosis is determined by consensus. A July 2007 review of Quality/Difficult Cases Rounds indicated: 40 cases were reviewed 10 cases were referred for outside consult 38 cases showed agreement between the QC Rounds consensus and the final diagnosis 4. Satisfaction Surveys - In 2006 and 2007 satisfactions surveys were undertaken to determine the degree to which surgeons were satisfied with the pathology laboratory service. The overall satisfaction ratings for 2007 showed improvement in satisfaction for the service as indicated by the table below: (the numbers indicate the number of responses for the rating) Poor Below Average Average Good Excellent 2006 3 9 10 13 2 2007 0 0 7 21 2 2

Eastern Health Volume 86 Page 003 CIHRT Exhibit P-3595 Page 3 EXTERNAL QUALITY ASSURANCE AND PROFICIENCY SURVEYS 2008 College of American Pathologists Survey (CAP) 1. HQIP Histologic Quality Improvement Program Frequency - Twice each year the laboratory submits slides Evaluation - Fixation, tissue processing and embedding, microtomy, staining, and coverslipping. Description - The survey is designed as an educational program to improve the quality of histologic slides. provides participant evaluation, educational critique, peer comparison data, and benchmarking data. It also provides reading material and on-line learning assessments. 2. MK - Immunohistochemistry Predictive Markers Frequency - Twice each year the laboratory receives slides Evaluation - Staining of a number of markers and pathologist interpretation Description Designed primarily as an educational program for IHC laboratories providing markers for diagnostic support. The CAP Immunohistochemistry committee no longer grades this program. 3. PM Immunohistochemistry Predictive Markers Frequency - Twice each year for ER and CD20 (One marker at each survey) Evaluation Staining and pathologist interpretation Description This survey is designed for laboratories performing immunohistochemistry procedures for predictive markers. 4. PIP Performance Improvement Program in Surgical Pathology Frequency Four times per year;10 cases each shipment Evaluation Designed for educational purposes only Description - Designed as an education and performance assessment tool for pathologists to compare their performance with that of their peers. 3

Eastern Health Volume 86 Page 004 CIHRT Exhibit P-3595 Page 4 5. NP - Neuropathology Quality Improvement Frequency Twice per year; 8 cases per shipment Evaluation Designed as educational program Description education program for pathologists to assess and improve their diagnostic skills and to learn of new developments in neuropathology American Society for Clinical Pathology (ASCP) Frequency Four times per year; 5 cases each shipment Evaluation Designed for educational purposes only Description - Designed as an education and performance assessment tool for pathologists to compare their performance with that of their peers. UK National External Quality Assessment Scheme (UK NEQAS) 1. Breast Pathology Hormonal Receptors ER and PR Frequency Four times per year; one receptor per survey, alternating between ER and PR. Evaluation Staining and pathologist interpretation of survey slide and in-house control Description IHC laboratories stain slides provided and also submit in-house control slide for evaluation. The aim is to identify poorperforming laboratories as soon as possible (reporting UK labs only). Due to the direct impact of ER/PR results on patient management, stringent performance monitoring mechanisms have been proposed. Scores are determined by a panel of four assessors awarding a mark out of 5, which are then totaled to give a score out of 20. The ratings are as follows: Acceptable > 13 / 20 Borderline < 13 / 20 Unacceptable < 10 / 20 4

Eastern Health Volume 86 Page 005 CIHRT Exhibit P-3595 Page 5 2. Breast Pathology Hormonal Receptors HER-2 Eastern Health IHC laboratory participates in the HER2 proficiency testing but is currently validating the protocol in its laboratory and is not performing patient testing. Frequency Four times per year Evaluation - Staining and pathologist interpretation of survey slide and in-house control Description IHC laboratories stain slides containing 4 breast carcinoma cell lines provided and also submit in-house control slide for evaluation..scoring will be determined following review by four expert assessors and is as follows: Acceptable All four cell lines show expected staining and intensity Acceptable but some disagreement between assessors Two of the 4 assessors have scored the cell lines as having acceptable stain. Unacceptable Three of four assessors have assessed the cell lines as unacceptable, indicating inappropriate staining. 3. Alimentary Tract Pathology CD117 Pilot Module Frequency Twice per year Evaluation - Staining and pathologist interpretation Description Specialist antibody for gastrointestinal stromal cell tumours (GIST). Scoring will be as follows: Acceptable > 12 / 20 Borderline 10 12 / 20 Unacceptable < 10 / 20 4. Lymphoid Pathology Frequency Four Times per year Evaluation Staining and pathologist interpretation of NEQAS and in-house slides. Description Four assessments per year with two antigens at each run. The gold standard for 2008 will be Cyclin D1 (Mantle Cell Lymphoma) Four different antibodies will be assessed along with the gold standard. Scoring is as follows: Acceptable > 12 / 20 Borderline 10 12 / 20 Unacceptable < 10 / 20 5

Eastern Health Volume 86 Page 006 CIHRT Exhibit P-3595 Page 6 EXTERNAL PROFICIENCY TESTING RESULTS College of American Pathologists (CAP) Proficiency Surveys and Anatomic Pathology Education Programs The College of American Pathologists offers proficiency and education program to promote laboratory performance improvement through an educational, peer - comparison program.. HQIP Fixation, Microtomy, Staining Predictive Marker (PM) CD20 Predictive Marker (PM) ER MK Survey PR 2006 Average to excellent results GOOD GOOD 2007 Average to excellent results GOOD GOOD * * The IHC laboratory participates in the CAP MK survey which is for educational purposes. The following antibodies are among those tested at Eastern Health IHC laboratory as part of the CAP proficiency MK Survey program and received a grade of GOOD in 2006: CD3 CD5 CD20 34BE12 The CAP no longer provides a grade for the markers in the MK program. The IHC laboratory continues to participate in the MK survey with good correlation for the technical IHC laboratory and pathologists interpretations. Comment: On its survey report to the laboratory, the College of American Pathologists recommends that the result of this inter-laboratory comparison not be used as a sole criterion for judging the performance of any individual clinical laboratory 6

Eastern Health Volume 86 Page 007 CIHRT Exhibit P-3595 Page 7 2. United Kingdom National External Quality Assessment Scheme (UK NEQAS) Results for ER and PR Acceptable scores for ER and PR will be greater than or equal to 13 / 20 2005 2006 #1 2006 #2 2007 #1 ER 16 16 20 18 PR 16 14 16 3. Additional Quality Assurance- Breast Pathology In addition to the proficiency testing programs of CAP and UK NEQAS, the Eastern Health Pathology laboratory conducts the following for breast cases: Dr. B Carter has indicated that Dr D. Cook and Dr. B. Carter send breast cases to Mt. Sinai for review, with excellent concordance to date In a memo to Dr. N. Denic, Dr. B. Carter indicates that in 2007, as of November 20, 147 estrogen receptor (ER) tests were performed at Eastern Health IHC laboratory. Of these cases, 35 were ER negative, a 24% negative rate. A total of 24 of the cases were sent to Mt Sinai for quality assurance with excellent concordance. Daily Laboratory Quality Control is performed with every Immunohistochemistry run. External proficiency testing must not be a sole measure of laboratory performance and must be considered in conjunction with intra-laboratory quality control and clinical correlation. All proficiency testing records are available on request. 7

Eastern Health Volume 86 Page 008 CIHRT Exhibit P-3595 Page 8 Filename: INDICATORS 2008 APRIL 23 2008 Directory: C:\Users\dws\Documents Template: C:\Users\dws\AppData\Roaming\Microsoft\Templates\Norma l.dotm Title: INDICATOR Subject: Author: wade-l Keywords: Comments: Creation Date: 23/04/2008 7:06:00 PM Change Number: 3 Last Saved On: 24/04/2008 9:07:00 AM Last Saved By: wade-l Total Editing Time: 43 Minutes Last Printed On: 29/08/2008 10:25:00 AM As of Last Complete Printing Number of Pages: 7 Number of Words: 1,539 (approx.) Number of Characters: 8,778 (approx.)